scholarly journals Impact of CD34 Cell Dose on Platelet Engraftment and Platelet Transfusions Following Autologous Hematopoietic Stem Cell Transplantation

2011 ◽  
Vol 17 (2) ◽  
pp. S205
Author(s):  
S. Shariatmadar ◽  
D. Pereira ◽  
R. Smith ◽  
M. Goodman
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Cell Dose ◽  
Platelet Transfusions

scholarly journals Thrombocytopenia and bleeding in pediatric oncology patients

Hematology ◽  
2012 ◽  
Vol 2012 (1) ◽  
pp. 499-505 ◽  
Author(s):  
Rachel S. Bercovitz ◽  
Cassandra D. Josephson
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Pediatric Oncology ◽  
Recurrent Bleeding ◽  
Transfusion Threshold ◽  
Hematopoietic Stem ◽  
Platelet Transfusions

Abstract Prophylactic platelet transfusions are the standard of care for patients with hypoproliferative thrombocytopenia after receiving chemotherapy or radiation for the treatment of malignancy, for BM replacement by leukemia or solid tumor, or in preparation for a hematopoietic stem cell transplantation.1 During this time of thrombocytopenia, these patients may receive both prophylactic platelet transfusions, which are given to prevent potentially life-threatening bleeding when a patient's platelet count drops below a predetermined threshold, and therapeutic platelet transfusions, which are given to treat active or recurrent bleeding. In the 1950s, the invention of the plastic blood bag allowed for the production and storage of platelet concentrates,2 and in the 1960s, it was recognized that prophylactic platelet transfusions effectively reduced hemorrhagic death in patients with newly diagnosed leukemia.3,4 In 1962, Gaydos published the paper that is frequently credited with the inception of the 20 000/μL platelet transfusion threshold.5 Despite a half-century of experience with prophylactic platelet transfusions, there are still insufficient data to provide clinicians with evidence-based guidelines specific to pediatric oncology and hematopoietic stem cell transplantation (HSCT) patients.

Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation

2009 ◽  
Vol 50 (9) ◽  
pp. 1434-1441 ◽  
Author(s):  
Jayesh Mehta ◽  
Jayesh Mehta ◽  
Olga Frankfurt ◽  
Jessica Altman ◽  
Andrew Evens ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Cell Dose ◽  
Reduced Intensity

CD3−cd(16+56)+ Cell Dose Is An Important Factor Determining Clinical Outcomes in Patients Undergoing Unmanipulated HLA-Identical Sibling Hematopoietic Stem Cell Transplantation

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4384-4384
Author(s):  
Xiaowen Tang ◽  
Biyun Peng ◽  
Mingqing Zhu ◽  
Wu Depei ◽  
Aining Sun ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Nk Cell ◽  
Hematopoietic Stem ◽  
Platelet Recovery ◽  
Cell Dose ◽  
Significant Difference

Abstract Background: It has been suggested that the dose of the cellular components in the graft may influence the outcome of transplantation, especially CD3 |CD(16+56)+ cell(NK cell) is believed to play an important role in improving the transplant outcome in terms of preventing graft-versus-host disease(GVHD) and graft rejection, and as a mediator of the graft-versus-leukemia(GVL) effect. The current study attempted to evaluate the role of CD3−CD(16+56)+ cell dose on the outcome of HLA-identical sibling hematopoietic stem cell transplantation. Methods: We retrospective analyzed the outcomes of 72 patients receiving HLA-identical sibling hematopoietic stem cell transplantation between July 2005 and May 2008 in the first Affiliated Hospital of Soochow University. Diagnoses of these patients included acute leukemia(AL)(n=34), chronic myeloid leukemia(CML) (n=29), aplastic anemia(AA) (n=4), malignant lymphoma (n=3) and multiple myeloma (n=2). The median follow-up time is 19 months (range 0.5–36 months) after transplantation. Transplanted doses of CD3 |CD(16+56)+ cell were analyze in relation to engraftment, GVHD, infectious events, relapse and survival. Result: The median dose of NK cell in bone marrow grafts from patients receiving G-CSF-mobilized was 0.91× 107/Kg. Therefore the group received a dose of CD3 |CD(16+56)+ cell above 0.91×107/Kg wass a higher group. There were no significant difference between two groups for neutrophil and platelet recovery. The incidence of II°-‡W°aGVHD in low group was much more than that of high group(41%VS 18.2%, P<0.05). and there was a significantly higher incidence of infection in patients receiving a lower dose of CD3 |CD(16+56)+ cell (46.1%VS 21.2%, P<0.05). However there was no significant association between CD3-CD(16+56)+ cell and either cGVHD or relapse. Conclusions: High dose of CD3−CD(16+56)+ cell may play an important role in improving the outcome of transplantation in terms of reducing aGVHD and infection.

Sign in / Sign up

Export Citation Format

Share Document